124 related articles for article (PubMed ID: 8545600)
1. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium.
Normann PT; Frøysa A; Svaland M
Scand J Clin Lab Invest; 1995 Aug; 55(5):421-6. PubMed ID: 8545600
[TBL] [Abstract][Full Text] [Related]
2. Acute hemodynamic effects of nonionic and ionic magnetic resonance contrast media in intravenous bolus injection in rats.
Masui T; Takehara Y; Aoshima R; Kaneko M
Invest Radiol; 1994 Jun; 29 Suppl 2():S189-91. PubMed ID: 7928226
[No Abstract] [Full Text] [Related]
3. [Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].
Sinitsyn VE; Kornienko VN; Nikitin VG; Pronin IN; Ternovoĭ SK; Tiutin LA; Iakobson MG
Vestn Rentgenol Radiol; 1995; (4):5-11. PubMed ID: 8571538
[TBL] [Abstract][Full Text] [Related]
4. In vivo stability and excretion of gadodiamide (GdDTPA-BMA), a hydrophilic gadolinium complex used as a contrast enhancing agent for magnetic resonance imaging.
Normann PT; Hals PA
Eur J Drug Metab Pharmacokinet; 1995; 20(4):307-13. PubMed ID: 8983938
[TBL] [Abstract][Full Text] [Related]
5. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.
Tweedle MF; Wedeking P; Kumar K
Invest Radiol; 1995 Jun; 30(6):372-80. PubMed ID: 7490190
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of gadodiamide injection and gadopentetate dimeglumine in anesthetized dogs.
Peters JL; Shaw DD
Acta Radiol; 1993 Sep; 34(5):510-6. PubMed ID: 8369191
[TBL] [Abstract][Full Text] [Related]
8. Determination of dysprosium in monkey serum by inductively-coupled plasma atomic emission spectrometry (ICP-AES) after the administration of Sprodiamide Injection, a new contrast medium for magnetic resonance imaging.
Lai JJ; Jamieson GC
J Pharm Biomed Anal; 1993; 11(11-12):1129-34. PubMed ID: 8123724
[TBL] [Abstract][Full Text] [Related]
9. Measurement of serum calcium concentration after administration of gadoversetamide in dogs.
Wible JH; Hynes MR
Radiology; 2004 Oct; 233(1):158-64. PubMed ID: 15454620
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of gadodiamide injection in paediatric MR imaging.
Hanquinet S; Christophe C; Greef DD; Gordon P; Perlmutter N
Pediatr Radiol; 1996 Nov; 26(11):806-10. PubMed ID: 8929382
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.
Svaland MG; Christensen T; Lundorf E
Acta Radiol; 1994 Jul; 35(4):396-9. PubMed ID: 8011392
[TBL] [Abstract][Full Text] [Related]
12. MR imaging of pituitary region lesions with gadodiamide injection.
Hald JK; Skalpe IO; Bakke SJ; Nakstad PH
Acta Radiol; 1994 Jan; 35(1):65-9. PubMed ID: 8305277
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced MRI with gadodiamide injection in rat disease models.
Yamada K; Miyahara K; Sato H; Nakayama W; Sato M; Hirose T; Kato H; Ikehira H; Tateno Y; Sugihara H; Furuhama K
J Vet Med Sci; 1996 Apr; 58(4):291-5. PubMed ID: 8741259
[TBL] [Abstract][Full Text] [Related]
14. Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5 T.
Demaerel P; Marchal G; Wilms G; Van Calenbergh F; De Greef D; Børseth A; Baert AL
Neuroradiology; 1994 Jul; 36(5):355-9. PubMed ID: 7936174
[TBL] [Abstract][Full Text] [Related]
15. Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker.
Berg KJ; Lundby B; Reinton V; Nordal KP; Rootwelt K; Smith HJ
Nephron; 1996; 72(2):212-7. PubMed ID: 8684529
[TBL] [Abstract][Full Text] [Related]
16. Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.
Akeson P; Larsson EM; Kristoffersen DT; Jonsson E; Holtås S
Acta Radiol; 1995 May; 36(3):300-6. PubMed ID: 7742127
[TBL] [Abstract][Full Text] [Related]
17. [Gadodiamide and gadolinium-DTPA as intravenous media in computed tomography].
Engelbrecht V; Koch JA; Rassek M; Mödder U
Rofo; 1996 Jul; 165(1):24-8. PubMed ID: 8765359
[TBL] [Abstract][Full Text] [Related]
18. Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing.
Löwe A; Balzer T; Hirt U
Invest Radiol; 2005 Aug; 40(8):521-5. PubMed ID: 16024990
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the safety of the standard dose and a higher dose of gadodiamide injection for MR imaging of the central nervous system.
Svaland MG; Lundby B; Kristoffersen DT
J Magn Reson Imaging; 1994; 4(3):419-23. PubMed ID: 8061442
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of the tolerability of gadodiamide, a new nonionic contrast agent in MRI of the central nervous system].
Aslanian V; Lemaignen H; Bunouf P; Schiratti M; Lambrechts M; Lundby B; Borseth A; Svaland M
J Radiol; 1995 Jul; 76(7):431-4. PubMed ID: 7473377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
